Group 1 - The core viewpoint is that several fund companies have collectively downgraded the valuation of the Hong Kong-listed company NuoHui Health, with some estimates dropping by over 90% from the pre-suspension price of 14.14 HKD to as low as 1.2 HKD [1] - On June 26, Bosera Fund announced a valuation of 3.33 HKD per share for NuoHui Health, while Great Wall Fund set its valuation at 1.2 HKD per share, indicating a significant reduction in perceived value [1] - NuoHui Health has been suspended since March 2024 due to allegations of financial fraud and audit concerns, leading to multiple valuation downgrades by various fund companies [1] Group 2 - In addition to NuoHui Health, the A-share market's ST Zitian also faced valuation downgrades, with Huaxia Fund reducing its valuation from 8.74 CNY to 2.5 CNY, reflecting a decline of over 70% [3] - The stringent valuation adjustments by fund companies for NuoHui Health and ST Zitian are attributed to financial uncertainties and operational risks, highlighting a trend of increasing risk management standards within the public fund industry [3] - Fund managers are reportedly becoming more selective about investment targets, with a stronger emphasis on company fundamentals, particularly avoiding ST stocks [3]
诺辉健康遭遇基金公司“集体看空”